Czech universities and research institutes (as well as their counterparts in other European countries) are stimulated to cooperate more closely with business. The need to intensify knowledge transfer, commercialization of R&D outcomes, collaborative research, spin-off companies´ creation, etc. has been increasingly emphasized and supported. On the other hand, they are several limitations (legal as well as economic) to success or failure of various modes of cooperation. Which modes have proved to be the most successful? Why is the cooperation between research organizations and business still seen as not well developed? What is the most incredible story of technology transfer in the last 25 years in the Czech Republic?

1. CONFERENCE ON UNIVERSITY &
BUSINESS COOPERATION
IN CENTRAL EUROPE:
BUDAPEST,
4 – 5 DECEMBER 2017

2. CHALLENGES AND MAIN BARRIERS IN
RDI COOPERATION:
CASE STUDY OF THE CZECH REPUBLIC
ALEŠ VLK

3. BASED ON:
• SELECTED CONCEPTUAL
APPROACH
• PERSONAL EXPERIENCE
– CZECHINVEST,
MINISTRY, CONSULTING
• EXAMPLES, STORIES

4. CONCEPTUAL FRAMEWORK
• COLLABORATION IN R&D (JOINT ACTIVITIES,
CONTRACT RESEARCH, CONSULTING)
• PERSONNEL MOBILITY
• TRAINING AND EDUCATION
• COMMERCIALIZATION OF R&D RESEARCH
(LICENSING, PATENTS, START-UPS)
• INFORMAL NETWORKS
(TECHNOPOLIS, 2010)

5. WHAT WE HAVE
STRATEGIES
MOTTOS
APPEALS
MEASURES
MENTAL BARRIERS
DOMESTIC LEGAL
FRAMEWORK
EUROPEAN
REGULATION

6. EUROPEAN REGULATION
• EU COMPETITION RULES – DIRECT
INFORCEMENT
• BASED ON THE TREATY ON THE FUNCTIONING
OF THE EU (TFEU) – ARTICLES 101 – 109
• STATE AID IN R&D
• GENERAL BLOCK EXEMTION REGULATION
(2014)
• FRAMEWORK FOR STATE AID FOR RDI (2014)

7. WHAT DOES IT MEAN?
STATE AID
UNIVERSITIES
COMPANIES MARKET

8. WHAT DOES IT MEAN?
• 100 PERCENT FUNDED R&D INFRASTRUCTURE
• ECONOMIC X NON-ECONOMIC ACTIVITIES
• LIMITED CAPACITIES OF R&D
INFRASTRUCTURE USED FOR ECONOMIC
ACTIVITIES
• STATE AID FROM UNIVERSITIES INTO
BUSINESS
• IP PROTECTION

9. WHAT DOES IT MEAN?
• LIMITATIONS FOR ECONOMIC ACTIVITIES –
CONTRACT RESEARCH, CONSULTANCY …
• NO LIMITATION FOR NON-ECONOMIC
ACTIVITES – TECHNOLOGY TRANSFER
(LICENSING, SPIN OFFS)
• VALUE FOR MONEY

10. DOMESTIC BARRIERS - CZ
• LIMITED SPACE FOR PUBLIC UNIVERSITIES TO
USE PUBLIC FUNDING FOR THE „THIRD ROLE“
ACTIVITIES (SPIN OFFS)
• MOST OF THE TIME DEVOTED TO RESEARCH
(PUBLISHING) AND PROJECT ADMINISTRATION
• LACK OF TIME FOR TEACHING AND
ADDITIONAL (THOUGH USEFUL) ACTIVITIES

11. DOMESTIC BARRIERS - CZ
• TAX INCENTIVES – INTRODUCED IN 2005
• SINCE 2014 R&D SERVICES FROM RESEARCH
ORGANIZATION CAN BE ALSO CLAIMED

12. YET …
INSTITUTE OF ORGANIC
CHEMISTRY AND BIOCHEMISTRY
CZECH ACADEMY OF SCIENCES
THE INSTITUTE CARRIES OUT
FUNDAMENTAL RESEARCH IN
ORGANIC CHEMISTRY,
BIOCHEMISTRY AND RELATED
DISCIPLINES, FOCUSING IN
PARTICULAR ON MEDICAL AND
ENVIRONMENTAL
APPLICATIONS.

13.  ESTABLISHED 1952
 LEADING SCIENTIFIC INSTITUTION IN THE CZECH
REPUBLIC
 EMPHASIS ON INTERDISCIPLINARY APPROACH
 46 GROUPS, 250 PUBLICATIONS/YEAR
 OVER 750 EMPLOYEES, 180 STUDENTS
 INTERNATIONAL ENVIRONMENT – 25% EMPLOYES FROM
ABROAD
 CUTTING-EDGE FACILITIES & TECHNOLOGIES
 COLLABORATION WITH STRONG COMMERCIAL
PARTNERS

14. ANTIVIROTICS
DUVIRA (SPOFA)
VISTIDE®, VIREAD®, HEPSERA®, TRUVADA®, ATRIPLA®, COMPLERA®,
STRIBILD®, GENVOYA®, ODEFSEY® (GILEAD)
HORMONES
OXYTOCIN, DESMOPRESSIN, TERLIPRESSIN/GLYPRESSIN (FERRING-
LÉČIVA)
CARBETOCIN/DURATOCIN (NORDIC GROUP, FERRING)
DERMATOLOGICS
DERMAZULEN (ZENTIVA – SANOFI GROUP)
CANCEROSTATICS
5-AZA-2’-DEOXYCYTIDINE/DECITABINE (JOHNSON & JOHNSON)

15. STORY BEHIND
1980s – HOLY, DE CLERK, MARTIN
IOCB PRAGUE, KU LEUVEN
GILEAD – BASED ON PATENTS OF
HOLY (TURNOVER MORE THAN 15
BILLION DOLLARS)

16. KEY LICENSES
1992 TENOFOVIR
2013 TENOFOVIRALFENAMIDE
2016 MERCK – RESEARCH TOOL
2017 NOVO NORDISK – OBESITY
TREATMENT

19. • TOP BASIC RESEARCH
• LIMITED APPLIED AND CONTRACT
RESEARCH
• REGULAR CHECKS – WHAT IS IT
GOOD FOR? CAN IT BE APPLIED?
• LICENSING
• YET, THE BIGGEST ADDED VALUE
FOR THE SOCIETY
LESSONS TO LEARN?

20. THANK YOU FOR YOUR ATTENTION
www.teri-institute.eu